Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource
Christina Kapizioni, R Desoki, Danielle Lam, et al.
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 6, pp. 790-800
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
Hannah Gordon, Silvia Minozzi, Uri Kopylov, et al.
Journal of Crohn s and Colitis (2024)
Open Access | Times Cited: 49
Recent advances in epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years
Jian Wan, Jiaming Zhou, Zhuo Wang, et al.
Chinese Medical Journal (2025)
Open Access | Times Cited: 1
Comprehensive care of ulcerative colitis: new treatment strategies
Thanaboon Chaemsupaphan, Arteen Arzivian, Rupert W. Leong
Expert Review of Gastroenterology & Hepatology (2025)
Closed Access
Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment
Ali Atay, Yavuz Çağır, Mehmet Ergül, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1228-1228
Open Access
Temporal Trends in the Use of Biological Agents in Patients with Inflammatory Bowel Disease: Real-World Data from a Tertiary Inflammatory Bowel Disease Greek Center During a 5-Year Period
Panagiotis Markopoulos, Aikaterini Gaki, Georgios Kokkotis, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1357-1357
Open Access
First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn’ disease, but not in ulcerative colitis
Eva Supovec, Jurij Hanžel, Gregor Novak, et al.
European Journal of Gastroenterology & Hepatology (2025)
Closed Access
A practical approach to positioning therapies in ulcerative colitis
Russell Yanofsky, David T. Rubin
Journal of the Canadian Association of Gastroenterology (2025) Vol. 8, Iss. Supplement_2, pp. S6-S14
Open Access
Small Bowel Motility Quantified by Cine MRI to Predict Longer-Term Response in Patients with Crohn’s Disease Commencing Biological Therapy: The Motility Study
Andrew Plumb, Gordon W. Moran, Kashfia Chowdhury, et al.
Inflammatory Bowel Diseases (2025)
Closed Access
Treatment sequencing in inflammatory bowel disease : towards clinical precision medicine
Léa Sequier, Bénédicte Caron, Sailish Honap, et al.
Best Practice & Research Clinical Gastroenterology (2025), pp. 101994-101994
Closed Access
Genetic Polymorphisms on TNFA, TNFRSF1A, and TNFRSF1B Genes Predict the Effectiveness of Anti-TNF-α Treatment in Inflammatory Bowel Disease Patients
Michelangelo Rottura, Igor Pirrotta, Domenico Antonio Giorgi, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 669-669
Open Access
Persistence and Efficacy of Ustekinumab in Crohn’s Disease After Anti-TNF Failure: An Observational Study
I. Latras-Cortés, J. C. Sáez Hortelano, Patricia Suárez-Álvarez, et al.
Digestive Diseases and Sciences (2025)
Closed Access
Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn’s Disease: A Review of Comparative Effectiveness Studies
Mohmmed Sharip, Nilanga Nishad, Lushen Pillay, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 8, pp. 2187-2187
Open Access | Times Cited: 3
Switching within versus out of class following first-line TNFi failure in ulcerative colitis: real-world outcomes from a German claims data analysis
Evi Zhuleku, Daniel Wirth, R Nissinen, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 3
Real-world Positioning and Effectiveness of First- and Second-Line Biological Therapy in Inflammatory Bowel Diseases
Joana Revés, Joana Torres
Journal of Crohn s and Colitis (2024) Vol. 18, Iss. 6, pp. 787-789
Open Access | Times Cited: 2
Targeting AQP9 enhanced the anti-TNF therapy response in Crohn's disease by inhibiting LPA-hippo pathway
Minhao Yu, Yuan Shi, Yuan Gao, et al.
Pharmacological Research (2024) Vol. 203, pp. 107172-107172
Open Access | Times Cited: 2
Contribution of gut-derived T cells to extraintestinal autoimmune diseases
Qiaolin Wang, Yutong Wu, Qianjin Lu, et al.
Trends in Immunology (2024) Vol. 45, Iss. 9, pp. 639-648
Closed Access | Times Cited: 2
A plant-based diet is feasible in patients with Crohn’s disease
Line Birch Arvidsson, Helle Nygaard Lærke, Charlotte Lauridsen, et al.
Clinical Nutrition ESPEN (2024) Vol. 64, pp. 28-36
Open Access | Times Cited: 2
Treatment trajectories and outcomes in inflammatory bowel disease: a tertiary single-centre experience
Kim Wagner, Tanja M. Müller, Francesco Vitali, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 2
Long‐Term Outcomes of an Infliximab‐First Versus Vedolizumab‐First Treatment Strategy in Biologic‐Naïve Patients With Ulcerative Colitis
Austin Haynesworth, Kun‐Huei Yeh, Han Hee Lee, et al.
Alimentary Pharmacology & Therapeutics (2024)
Closed Access | Times Cited: 1
Ultrasound of the bowel with a focus on IBD: the new best practice
Christina Merrill, Stephanie R. Wilson
Abdominal Radiology (2024)
Closed Access | Times Cited: 1
Effectiveness of biologic therapies in achieving treatment targets in inflammatory bowel disease; real-world data from the Middle East (ENROLL study)
Mohammad Shehab, Ahmad Alfadhli, Israa Abdullah, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Letter: Extending the Measurement of Inflammatory Bowel Disease Severity to Include Patient Important Outcomes
Angela Forbes
Alimentary Pharmacology & Therapeutics (2024)
Closed Access | Times Cited: 1
Vedolizumab versus ustekinumab in Crohn’s disease with prior anti-tumor necrosis factor failure: an updated meta-analysis
Natália Junkes Milioli, Matheus Vanzin Fernandes, Tulio Loyola Correa, et al.
European Journal of Gastroenterology & Hepatology (2024) Vol. 36, Iss. 9, pp. 1068-1074
Closed Access
How comparative studies can inform treatment decisions for Crohn’s disease
Giuseppe Privitera, Cristina Bezzio, Arianna Dal Buono, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 9, pp. 955-972
Closed Access
Nested Randomized Controlled Trials in Large Databases: An Opportunity for Inflammatory Bowel Disease?
María José Temido, Sailish Honap, Silvio Danese, et al.
Journal of Crohn s and Colitis (2024)
Open Access
Page 1 - Next Page

Scroll to top